Summary of Alexandria Real Estate Equities (ARE) Q4 2025 Earnings Call

1Key Financial Results and Metrics

FFO per Share: $2.16 for Q4 2025; $9.01 for the full year, aligning with prior guidance.

Leasing Volume: 1.2 million square feet in Q4, a 14% increase from the prior 4-quarter average.

Occupancy Rate: 90.9% at year-end, up 30 basis points from the previous quarter.

Same-Property NOI: Down 6% for Q4; down 3.5% for the full year.

Dispositions: Completed $1.5 billion across 26 transactions in Q4, significantly contributing to a strong balance sheet with a leverage ratio of 5.7x.

2Strategic Updates and Business Highlights

Focus on Dispositions: The company aims to continue reducing its capital expenditures and maintain a flexible balance sheet, with a target of $2.9 billion in dispositions for 2026, primarily non-core assets and land.

Investor Day Strategy: The company is executing a strategic plan to navigate the challenging life science landscape, emphasizing leasing vacant and redevelopment spaces.

Cost Management: Achieved $51.3 million in G&A cost savings, representing a 30% reduction year-over-year.

3Forward Guidance and Outlook

2026 Guidance: Anticipates same-property NOI performance to be down/up 8.5% at the midpoint, with a projected decline in occupancy in Q1 2026 due to lease expirations.

FFO Guidance for Q4 2026: Reiterated guidance of $1.40 to $1.60, expected to represent the trough for the year.

Leverage Expectations: Short-term increase in leverage anticipated in Q1 2026, with improvement expected in subsequent quarters as dispositions progress.

4Bad News, Challenges, or Points of Concern

Market Conditions: The life science sector remains in a bear market, with ongoing challenges in the regulatory environment and a cautious approach from tenants regarding expansion.

Declining Metrics: Same-property NOI has decreased, and occupancy is expected to dip in Q1 2026 due to significant lease expirations.

Impairments: Recognized $1.45 billion in impairments in Q4, primarily related to land and non-core assets, reflecting oversupply in certain markets.

Tenant Wind-Downs: Anticipated revenue headwinds of approximately $6 million per quarter due to tenant wind-downs, driven by clinical failures and capital constraints.

5Notable Q&A Insights

Leasing Sentiment: While there is cautious optimism due to increased venture capital funding, decision-making remains slow, particularly among public biotech companies.

Development Strategy: The company is evaluating its development pipeline and may pivot to office use for certain properties based on market demand.

Investor Interest: The stock's recent performance may reflect a rotation among investors, with interest from those looking for value in the life sciences sector amidst ongoing volatility.

Future Development Exposure: The company aims to reduce development exposure to around 10% of total assets, focusing on high-quality, income-producing assets. This summary encapsulates the key points from the earnings call, highlighting ARE's financial performance, strategic direction, and the challenges it faces in the current market environment.